All In Biotech

NDA 020869 · Thea Pharma

Cosopt

Dorzolamide Hydrochloride, Timolol Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Nov 23, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Apr 7, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

82

19 Phase 3, 2 recruiting

FAERS reports

5,768

3,918 serious, 342 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 17, 2024.

COSOPT ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14) ] . COSOPT is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. ( 1 )

Mechanism: COSOPT is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • COSOPT · DORZOLAMIDE HYDROCHLORIDE EQ 2% BASE; TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT1

Clinical trials

Interventional ClinicalTrials.gov studies with "Dorzolamide" as an intervention, any sponsor and status, largest first.

All 82 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective501
  • intraocular pressure increased324
  • eye irritation321
  • eye pain285
  • glaucoma277
  • fatigue239
  • off label use230
  • dyspnoea218
  • ocular hyperaemia218
  • fall212
  • vision blurred206
  • nausea195

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004110
2005118
2006117
2007165
2008166
2009191
2010246
2011271
2012294
2013330
2014315
2015359
2016400
2017391
2018351
2019363
2020346
2021205
2022228
2023216
2024201
2025244
2026140

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cosopt (Dorzolamide HCl/Timolol Maleat)

2024 spending

$634K

Beneficiaries

758

1,932 claims

Per beneficiary

$836

$22.37 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$384,115
2024$633,606

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 322 on PubMed

Sponsor: Thea Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.